We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Medicines Agency (EMEA) has published five product-specific final industry guidelines for the development of biogenerics, including guidances for products containing insulin, somatropin and recombinant granulocyte-colony stimulating factor.